Moleculin Biotech, Inc. has entered into an agreement with the University of Texas Medical Branch at Galveston (UTMB) to conduct research on Moleculin’s portfolio of molecular inhibitors, including drug candidate, WP1122, for antiviral properties against a range of viruses, including Coronavirus. UTMB’s Center for Biodefense and Emerging Infectious Diseases collaborates with the Galveston National Laboratory, which is funded by NIAID, the U.S. Department of Defense, the U.S. Centers ...